News

Cost of bowel cancer screening estimated at £40 million

30-Apr-08

The bowel cancer screening programme in England could cost over £40 million.

UK researchers have calculated that for a hypothetical population of 500,000 people, 66,956 of who would be aged 60-74 and eligible for screening, an estimated 34 cancers would be detected at a cost of £394,157.

Extrapolating this to the whole of England, with an estimated population of 50,762,900, the cost would be £40,017,104. 

Cost is likely to rise as more become eligible for colonoscopy, say the researchers from the UK's Public Health Resources Unit.

rachel.liddle@haymarket.com

Gut Online 2008

Comment below and tell us what you think 

Comments

Graham Brown

30/04/2008

Now we just need someone to finish the research and find out how much this early intervention would ultimately save the NHS.Then we would have a substantive article rather than yet another headline grabbing sound bite.

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Healthcare Republic Forums

 

Registrar

Assessment guide is useful for all

Mock scenarios and helpful exercises make this book more than an exam guide, says Dr Lizzie Croton. Read more

Women's health - Terminate pregnancies

Requests for pregnancy termination should be handled with sensitivity, writes Dr Mona Kular. Read more

Clinical skills assessment

In the first of a regular look at the nMRCGP, Dr Daryl Goodwin explains how to pass the CSA. Read more

Show all articles

 

Latest Clinical Articles

Sjogren's syndrome

Contributed by Dr Jeffery Lee, consultant rheumatologist, Barnet Hospital, Hertfordshire. Read more

Chronic kidney disease

Section 1: Epidemiology and classification  Chronic kidney disease (CKD) encompasses abnor... Read more

Acute kidney injury

Contributed by Dr Stephan Brincat, specialist registrar, and Dr Rachel Hilton, consultant nephrologi... Read more

Show all clinical articles

MIMS Product News

New drug - Eucreas

Eucreas (vildagliptin + metformin) is a new fixed-dose combination treatment for patients inadequate... Read more

New drug - Galvus

Novartis has launched a new oral hypoglycaemic for the treatment type II diabetes. Read more

Coversyl formulation change

Coversyl and Coversyl Plus have been discontinued and replaced by Coversyl Arginine and Coversyl Arg... Read more

Jobs

 

Job of the Week